RxDoctor Payments Data

Maria Gonzalez, MD

Internal Medicine · Wheeling, ILNPI 1912988783

Payments from drug & device makers

$2,286in general payments, 2019–2025

Across 128 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$643
  • Novo Nordisk$367
  • Lilly USA, LLC$352
  • Johnson & Johnson$309
  • Merck$242
  • AbbVie$50
  • plus $322 from 13 others

What the payments were for

  • Food & beverage$2,286100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca40$643
Novo Nordisk17$367
Lilly USA, LLC17$352
Johnson & Johnson21$309
Merck15$242
AbbVie2$50
Watermark Medical, Inc.1$41
Spineology Inc.1$35
Amgen(2 entities)2$33
Kowa Pharmaceuticals America, Inc.2$31
Metuchen Pharmaceuticals2$26
Coloplast1$24
Pfizer1$21
Ardelyx, Inc.1$21
Xeris Pharmaceuticals, Inc.1$21
GSK1$20
Lupin Inc.1$18
Exact Sciences1$16
Novartis1$16

How this compares

$2,286 in reported general payments places this provider in the 85th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$17,602
Medicare patients
46
Services billed
232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin42$41,779
FarxigaDapagliflozin Propanediol32$20,800
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$6,646
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$5,545
Ultra-Fine Short Pen NeedlePen Needle, Diabetic15$1,935
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$1,562
Gabapentin75$1,476
Metoprolol Succinate60$1,422
Atorvastatin Calcium120$990
Omeprazole66$819
Famotidine31$643
Fenofibrate16$510
Ezetimibe15$475
Losartan Potassium94$465
Paroxetine Hcl33$450

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$643$20,80032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Wheeling

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →